Clinical trial
Reliable Inhibition of Thrombocyte Activity: Comparison of PL2200 Aspirin Capsules, 325 mg and Enteric-Coated Aspirin (RITE Study)
NCT02008942 is registered in ClinicalTrials.gov with PLx Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Reliable Inhibition of Thrombocyte Activity: Comparison of PL2200 Aspirin Capsules, 325 mg and Enteric-Coated Aspirin (RITE Study)
- Lead sponsor
- PLx Pharma
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2014
- Completion date
- April 30, 2014
- Enrollment
- 57 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.